Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Wolinsky

Showing results (311-320 of 331) with videos related to

Pageof 34
Sort By:
Lancet (London, England)|February 1, 2016
Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trialFred Lublin, David H Miller, Mark S Freedman, et al.
The Journal of Experimental Medicine|September 8, 1999
Measuring recent thymic emigrants in blood of normal and HIV-1-infected individuals before and after effective therapyL Zhang, S R Lewin, M Markowitz, et al.
Annals of Neurology|July 18, 2001
Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosisW I McDonald, A Compston, G Edan, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|November 5, 2019
Diroximel fumarate (DRF) in patients with relapsing-remitting multiple sclerosis: Interim safety and efficacy results from the phase 3 EVOLVE-MS-1 studyRobert T Naismith, Jerry S Wolinsky, Annette Wundes, et al.
The Lancet. Neurology|September 22, 2024
Safety and efficacy of evobrutinib in relapsing multiple sclerosis (evolutionRMS1 and evolutionRMS2): two multicentre, randomised, double-blind, active-controlled, phase 3 trialsXavier Montalban, Patrick Vermersch, Douglas L Arnold, et al.
Lancet (London, England)|May 28, 2026
Efficacy and safety of ocrelizumab in primary progressive multiple sclerosis, including older patients and those with more advanced disease (ORATORIO-HAND): a multicentre, double-blind, randomised, placebo-controlled, phase 3b studyGavin Giovannoni, Laura Airas, Riley Bove, et al.
Science (New York, N.Y.)|April 15, 2000
HIV-1 nomenclature proposalD L Robertson, J P Anderson, J A Bradac, et al.
The New England Journal of Medicine|December 22, 2016
Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple SclerosisStephen L Hauser, Amit Bar-Or, Giancarlo Comi, et al.
Neurology|June 8, 2023
Polygenicity of Comorbid Depression in Multiple SclerosisKaarina Kowalec, Kathryn C Fitzgerald, Amber Salter, et al.
The New England Journal of Medicine|December 22, 2016
Ocrelizumab versus Placebo in Primary Progressive Multiple SclerosisXavier Montalban, Stephen L Hauser, Ludwig Kappos, et al.
Pageof 34

Showing results (311-320 of 331) with videos related to

Sort By:
Pageof 34
Lancet (London, England)|February 1, 2016
Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trialFred Lublin, David H Miller, Mark S Freedman, et al.
The Journal of Experimental Medicine|September 8, 1999
Measuring recent thymic emigrants in blood of normal and HIV-1-infected individuals before and after effective therapyL Zhang, S R Lewin, M Markowitz, et al.
Annals of Neurology|July 18, 2001
Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosisW I McDonald, A Compston, G Edan, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|November 5, 2019
Diroximel fumarate (DRF) in patients with relapsing-remitting multiple sclerosis: Interim safety and efficacy results from the phase 3 EVOLVE-MS-1 studyRobert T Naismith, Jerry S Wolinsky, Annette Wundes, et al.
The Lancet. Neurology|September 22, 2024
Safety and efficacy of evobrutinib in relapsing multiple sclerosis (evolutionRMS1 and evolutionRMS2): two multicentre, randomised, double-blind, active-controlled, phase 3 trialsXavier Montalban, Patrick Vermersch, Douglas L Arnold, et al.
Lancet (London, England)|May 28, 2026
Efficacy and safety of ocrelizumab in primary progressive multiple sclerosis, including older patients and those with more advanced disease (ORATORIO-HAND): a multicentre, double-blind, randomised, placebo-controlled, phase 3b studyGavin Giovannoni, Laura Airas, Riley Bove, et al.
Science (New York, N.Y.)|April 15, 2000
HIV-1 nomenclature proposalD L Robertson, J P Anderson, J A Bradac, et al.
The New England Journal of Medicine|December 22, 2016
Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple SclerosisStephen L Hauser, Amit Bar-Or, Giancarlo Comi, et al.
Neurology|June 8, 2023
Polygenicity of Comorbid Depression in Multiple SclerosisKaarina Kowalec, Kathryn C Fitzgerald, Amber Salter, et al.
The New England Journal of Medicine|December 22, 2016
Ocrelizumab versus Placebo in Primary Progressive Multiple SclerosisXavier Montalban, Stephen L Hauser, Ludwig Kappos, et al.
Pageof 34